Chronic obstructive pulmonary disease (COPD) is an irreversible or partially reversible disorder with slow progress (1), characterized by progressive airflow obstruction. Patients suffer from this disease for years and die prematurely from it or its complications (2).

Currently, COPD is the fourth major cause of death worldwide and is projected to rank fifth in 2020 (3). Cigarette smoking is generally thought to be a major risk factor for COPD due to the clear association of smoking and airway obstruction (4). However, smokers show considerable interindividual variation in their risk of developing airflow obstruction (5, 6). Interestingly, COPD is found to be more common among relatives of COPD smoker patients than unrelated smokers. Genetics may aid the discovery of novel therapeutic targets for this disease.

Presently, numerous genes have been implicated in the progression of COPD. For instance, alpha 1-antitrypsin deficiency (AATD) is demonstrated to be a clearly inherited risk factor of COPD. Specifically, smokers with AATD have a particularly high risk of developing COPD (10). Additionally, from a molecular perspective, a serial analysis of gene expression by Ning et al. (11) identified stress response genes such as cytokines and chemokines, and pro-apoptotic and anti-proliferation genes to be differentially expressed in COPD patients. Although many genetic factors have been identified, there is no known method for the effective treatment of COPD patients other than improving the symptoms and delaying disease progression (2).

Recently, personalized therapy has been applied in some diseases by subdividing patients into subtypes based on clinical heterogeneity (12). However, Goh et al. (13) reported that COPD has variable clinical phenotypes and it is thus not straightforward to develop individualized...
treatment programs for patients with this complex chronic disease. We therefore hypothesized that subdividing COPD patients into subtypes based on the expression of identified genetic factors may shed further light onto COPD risk factors and potentially allow personalized therapy in COPD patients.

**Material and Methods**

**Microarray data**

In this bioinformatics study, the gene expression dataset GSE76705 was downloaded from the Gene Expression Omnibus (GEO) database. Individuals analyzed in GSE76705 were Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) subjects donating whole blood as well as peripheral blood mononuclear cells from COPD Gene subjects. Gene expression profiling was undertaken on an Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133_Plus_2, Affymetrix Inc., Santa Clara, California, USA). The dataset contained data of 54676 probes in 229 COPD samples. We first normalized the original data using the robust multiarray average (RMA) method in Affy package, calculated the mean value and standard deviation, and then transformed expression values into standard normal distribution using Z-test. We then converted the probes into gene symbols using the Affy package. For multiple probes that mapped to the same gene symbol, their mean value was used as the gene expression value of that gene.

**Identification of COPD-related genes**

COPD-related genes were downloaded from OMIM (http://omim.org/) (14) all of which have key roles in the pathopoiesis of COPD. The Entrez Gene IDs were collected and were then converted into gene symbol. These genes were considered as candidate genes of COPD.

**Unsupervised hierarchical clustering**

Based on the expression values of the candidate genes in the 229 COPD samples of GSE76705, we constructed a similarity matrix using hierarchical clustering and the average clustering algorithm. The clustering result was assessed using the cophenetic correlation coefficient and the molecular subtypes of COPD were divided using the 'cutree' function in the R hclust package.

**Subtype-specific gene allocation**

After hierarchical clustering, the samples with similar expression profiles were clustered together with patients in different subtypes displaying specific molecular diversities. Since a number of genes may be differentially expressed in different subtypes, we compared the expression levels of candidate genes in different subtypes and allocated the candidate genes into different subtypes. In specific, first we assumed a total of n subtypes were obtained after hierarchical clustering. Next, to determine whether a gene was differentially expressed in a specific subtype, we calculated the P value of differential expression between this subtype and other n-1 subtype using t test. If P<0.05, this gene would be allocated to the subtype which shows a higher level of differential expression (12). Finally, each subtype had its own specific candidate gene set.

**Identification of specific functional pathway and gene of subtype**

To investigate the functions of these subtype-specific gene sets, we carried out KEGG pathway enrichment analysis using DAVID (http://david.abcc.ncifcrf.gov/) (15). The enrichment method was based on a corrected Fisher’s Exact Test and pathways with P<0.05 were considered as significantly enriched pathways.

**Pathway deviation score**

Since genes specific to different subtypes had different expression patterns, the pathways enriched by these specific genes may have different functional levels in different subtypes, and may thus be targeted in personalized therapies of COPD. Therefore, we quantitatively scored each pathway based on genes enriched in the pathway using equation 1

\[
A(P) = \frac{1}{N} \sum_{i=1}^{N} (X_i - Y_i)^2
\]

Where A(P) represents the deviation score of pathway P, N represents the number of differential genes in P, X i indicates the average expression value of gene i in the subtypes, and Y i represents the average expression value of gene i in all samples. The deviation level of pathway P in a given subtype was calculated as the cumulative sum of the Euclidean distances of all genes in pathway P. Finally, by comparing the deviation degree of pathway P among different subtypes, we identified: i. The pathways with differences among different COPD subtypes and ii. The associated regulatory genes involved in these pathways (12).

**Analysis of clinical features in molecularly-defined subtypes**

The distribution of clinical indicators of COPD, including age, gender, spirometric lung function (FEV1 and FEV1/FVC) and lung parenchymal destruction was compared in different subtypes. Significant differences of these four clinical indicators among the different subtypes were evaluated using analysis of variance (ANOVA) (16).

**Construction of predictive models**

Based on the deviation pathways in different subtypes, predictive models of different subtypes were constructed with a tree-based method by using the support vector machine (SVM) (17) classifier. The parameter settings were linear kernel, punish coefficient of 1 and a gamma value of 0. The true positive and false positive values were calculated using a 5-fold cross-validation method. The receiver operating characteristic (ROC) curve was
drawn for each subtype, and its stability and accuracy were evaluated by the area under the curve (AUC).

**Bioinformatic-based validation**

To validate the COPD molecular subtypes, we downloaded the gene expression dataset GSE71220 (18) from the GEO database, comprising 560 COPD and 57 control samples. Whole blood gene expression of COPD patients from the ECLIPSE study was analyzed using the Affymetrix Human Gene 1.1 ST microarray chip. After data preprocessing, as mentioned above, we clustered the 617 samples based on the expression of COPD-related genes using unsupervised hierarchical clustering analysis. Following that, we used the trained SVM classifier to predict the subtypes of the 617 samples.

**Results**

**Identification of chronic obstructive pulmonary disease-related genes**

A total of 195 Entrez Gene IDs were collected from OMIM, which were converted into 213 gene symbols. According to the expression values of these 213 genes in 229 COPD patients, we constructed the gene expression matrices. After normalization using the Z-Test, all gene expression values followed the normal distribution.

**Hierarchical clustering analysis**

The 229 samples were divided into three molecular subtypes, as shown in Figure 1A. The cophenetic correlation coefficient was 0.87, indicating no obvious outlier samples or redundant data. Subtypes 1, 2 and 3 contained 98, 53 and 78 samples respectively. The distribution of samples in the three subtypes is shown in Figure 1B.

**Subtype-specific gene allocation**

After allocation of samples into the three subtypes, we obtained three specific gene sets for each of the three subtypes. The number of genes in these gene sets were 166, 170 and 172, respectively. There were 160 common genes, such as transforming growth factor β1 (TGFβ1), epidermal growth factor receptor (EGFR), interleukin 13 (IL13), and B-Raf proto-oncogene, serine/threonine kinase, in the intersection of subtypes 1, 2 and 3.

**Subtype-specific functional pathway analysis**

To identify the functions enriched by the specific gene sets, we conducted KEGG pathway enrichment analysis for each subtype, and then selected the common pathways of the three subtypes. A total of 22 common pathways such as ‘hsa05214: Glioma, hsa04060: Cytokine-cytokine receptor interaction’, ‘hsa05222: Small cell lung cancer’ and ‘hsa04110: Cell cycle’ were obtained. Pathways unique to each subtype included hsa04062: Chemokine signaling pathway (subtype 1; CXCR1 and CXCR2), hsa04012: ErbB signaling pathway (subtype 2; EGFR), and hsa04630: Jak-STAT signaling pathway (subtype 2; IL13), etc.

**Pathway deviation scores**

To study the functional differences of the common pathways in the three subtypes, we calculated pathway deviation scores in subtypes (Fig.2). The pathways in subtype 2 exhibited the most obvious functional deviation, indicating that patients in subtype 2 may have higher risk for progression compared with subtypes 1 and 3.

**Subtype-specific clinical feature analysis**

FEV1 and FEV1/FVC were significantly lower in subtype 2 than that the other two subtypes (Fig.3). P-values of FEV1 and FEV1/FVC differences among the three subtypes were 0.03725 and 0.01613 respectively. There was no significant difference for age in the three subtypes (P=0.073), however, the number of female patients were significantly higher than males in subtypes 2 and 3 (P=0.00371).
**Fig. 2:** Pathway deviation scores of the subtypes. Subtypes 1, 2 and 3 are marked with blue, red and green lines respectively. Subtype 2 displays the most obvious functional deviation.

**Fig. 3:** Distribution of four clinical indicators in the three molecular subtypes. **A.** FEV1 ($P=0.03725$), **B.** FEV1/FVC ($P=0.01613$), **C.** Age ($P=0.073$), and **D.** Gender ($P=0.00371$).
Predictive model construction

On the basis of the 22 common pathways and their deviation scores, we constructed the predictive models using SVM. The ROC curves of the three subtypes (1, 2 and 3) are shown in Figure 4 with their average accuracies being 0.83, 0.80 and 0.87 respectively.

Data validation

To independently validate the subtypes, we examined the 617 COPD samples from the GSE71220 dataset and identified three subtypes after hierarchical clustering with most of the control samples being clustered in the control group (Fig.5). SVM models were then used to predict the subtypes of COPD patients. As shown in the confusion matrix in Table 1, the consistencies (ratio) of SVM models and hierarchical clustering in the three subtypes and the control group were approximately 70% (63.60%- 71.70%). To establish that the predicted COPD subtypes were non-random, we calculated the random probability of each subtype achieving the same ratio by randomly sampling samples for 10,000 times. The significant P values of the three subtypes (1, 2 and 3) were 0.0001, 0.0013 and 0.0004 respectively.

Discussion

These results suggest that although it is difficult for COPD to be clinically subtyped, it can be further divided into subtypes at the molecular level based on candidate gene expression levels, with our predictive models being able to distinguish different subtypes of COPD patients. To the best of our knowledge, this is the first study to subdivide COPD into molecular subtypes.

COPD is one of the most common inflammatory respiratory diseases (19). A study has reported that...
cytokines play critical roles in orchestrating the chronic inflammation of COPD by recruiting and activating multiple inflammatory cells in the respiratory tract (20). Cytokines are classified into several types including lymphokines, proinflammatory cytokines, growth factors, and chemokines. In the present study, three genes encoding growth factors (TGFβ1, EGFR) and lymphokines (IL13) were differentially expressed in all COPD patients, all of which are suggested to be implicated in COPD pathogenesis and present in the CTD database.

Chemokine signaling pathway (hsa04062) was a unique pathway in subtype 1, which was enriched by CXCR1 and CXCR2. Study has reported that in severe COPD and in an exacerbation in mild COPD, there is an increase in the number of neutrophils in the airways. The neutrophils form a major component of the inflammatory infiltrate in exacerbations of COPD (21, 22). Specially, neutrophils are stimulated and activated through binding of many CXC chemokines to their complementary receptors, notably CXCR1 and CXCR2 (23, 24). Importantly, antagonists targeted against CXCR1 and CXCR2 have been developed for the treatment of COPD (25). Taken together with our study, the pathway of Chemokine signaling pathway as well as CXCR1 and CXCR2 may serve as treatment targets in subtype 1 COPD.

Jak-STAT signaling pathway (hsa04630) was a unique pathway of subtype 2 and was enriched by IL13. IL13 is a Th2 cytokine produced by Th1 CD4+ T, Th2 CD4+ T cells, basophils, etc. It is implicated in recruiting inflammatory cells from the blood to the lung (26). It has been found to play a key role in airway inflammation (27). Zheng et al. (28) have suggested that increased expression of IL13 in the adult murine lung leads to emphysema. They have also revealed that pulmonary expression of transgenic IL13 in adult lungs gives rise to a COPD phenotype with inflammation-dependent emphysema. Importantly, van der Pouw Kraan et al. (29) revealed that human IL-13 gene was located on a chromosomal region associated with airway high reactivity that was a strong risk factor for COPD. Interestingly, a recent study of Grubek-Jaworska et al. (30) found no significant differences in the level of IL-13 between the COPD and asthma groups. Moreover, they found that IL-13 was undetectable in the induced sputum of 6 out of 26 cases of COPD. The different results between our studies may be due to the different tissue samples. Therefore, we speculated that Jak-STAT signaling pathway and IL-13 might be important candidate targets of subtype 2 COPD.

In addition to 'cell cycle' and 'cytokine-cytokine receptor interaction' pathways mentioned above, 'non-small cell lung cancer' and 'small cell lung cancer' were also identified as specific pathways to COPD. Interestingly, 'small cell lung cancer' had a higher pathway deviation score, suggesting a relationship between COPD and lung cancer. Studies have suggested that nonmalignant pulmonary conditions, such as chronic bronchitis, emphysema and COPD may increase the risk of lung cancer (31, 32). The correlation between COPD and lung cancer has also been assessed from a molecular perspective.

Lim et al. (33), for instance, reported that COPD was significantly correlated with EGFR mutations in non-smoker non-small-cell lung cancer patients. Importantly, the present study shows that EGFR was differentially expressed in COPD and was also present in the 'non-small cell lung cancer' enriched pathway. Taken together, the pathways associated with lung cancer suggest that COPD is a likely factor of lung cancer development.

Among the three COPD subtypes identified here, subtype 2 had higher pathway deviation scores, suggesting that patients in subtype 2 may have higher risk. In addition, analysis of clinical features showed that FEV1 and FEV1/FVC were also significantly lower in subtype 2. FEV1 provides a straightforward and inexpensive global measurement of airflow limitation and lung function, which is the main intermediate endpoint used in research and for the development of new COPD therapies (34). COPD usually starts in adulthood and causes a rapid decline in FEV1 (35). Additionally, initial airway obstruction is defined when the FEV1/FVC ratio is below the lower fifth percentile of a large healthy reference group (36). Therefore, these results were in accordance with pathway deviation scores, indicating the reliability of the molecular subtypes identified.

Moreover, the ROC curves of the three subtypes had higher average accuracies, indicating that the predictive models have sufficient discriminatory power to distinguish different subtypes of patients. Analysis of the gene expression dataset GSE71220, as a validation dataset, showed that, except for the control group, three COPD subtypes were attainable, further suggesting that COPD may be subdivided into several subtypes. The findings in this study, however, need to be validated with further clinical experiments. We are therefore in the process of collecting COPD samples, such as serum and peripheral blood mononuclear cells, to confirm our results.

Conclusion

The present study suggested that COPD could be further subdivided into multiple molecular subtypes. This may be useful in improving COPD therapy based on the molecular subtype of a patient. For instance, subtype 2 patients may require additional treatment given their expression profile being more severely affected. In addition, enrichment of lung cancer related pathways is suggestive of COPD being a risk factor of lung cancer development.

Acknowledgements

This work was financially supported by Chinese Medicine Science and Technology Development Project.
Fund of Shandong Province (project no. 2017-200), Postdoctoral Applications Research Project Fund of Qingdao (project no. 2016055) and The Affiliated Hospital of Qingdao University Youth Research Fund (2016). The authors declare no conflict of interest in this study.

Author’s Contributions
J.Z., Y.G.; Participated in the design of this study. W.C., X.H., Y.L.; Undertook the statistical analysis. J.L., J.S.; Carried out the study, together with J.L., F.W. and collected important background information. Y.G.; Drafted the manuscript. J.Z.; Conceived this study, participated in the design and helped in drafting the manuscript. All authors read and approved the final manuscript.

References
1. Littner MR. In the clinic. Chronic obstructive pulmonary disease. Ann Intern Med. 2011; 154(7): ITC4-ITC15.
2. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4): 347-365.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012.
4. Snider GL. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med. 1989; 40: 411-429.
5. Celedón JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, Demeo DL, et al. The transforming growth factor-β1 (TGFβ1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet. 2004; 13(15): 1649-1656.
6. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977; 115(2): 195-205.
7. Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014; 35(1): 1-6.
8. Lebowitz MD, Knudson RJ, Burrows B. Family aggregation of pulmonary function measurements. Am Rev Respir Dis. 1984; 129(1): 8-11.
9. Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997; 10(6): 1380-1391.
10. Foreraman MG, Michael C, Celedón JC. Genes and chronic obstructive pulmonary disease. Curr Opin Endocrinol Diabetes Obes. 2012; 19(2): 164-178.
11. Ping W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2004; 101(41): 14895-14900.
12. Wu T, Wang X, Li J, Song X, Wang Y, Zhang L, et al. Identification of personalized chemoresistance genes in subtypes of basal-like breast cancer based on functional differences using pathway analysis. PLoS One. 2015; 10(6): e0131183.
13. Goh F, Shaw JG, Savarimuthu FS, Vagabian A, Morrison L, Folan V, et al. Personalizing and targeting therapy for COPD—the role of molecular and clinical biomarkers. Expert Rev Respir Med. 2013; 7(6): 593-605.
14. Li J, Li Z, Kang Y, Li L. Review on the research progress of mining OMIM data. Shefeng Wu Yi Xue Gong Cheng Xue Za Zhi. 2014; 31(6): 1400-1404.
15. Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, Lane HC, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012; 28(13): 1805-1806.
16. Mitra V, Govorukhina N, Zwanenburg G, Hoefsloot H, Westra I, Smitde AK, et al. Identification of analytical factors affecting complex proteomics profiles acquired in a factorial design study with analysis of variance: simultaneous component analysis. Anal Chem. 2016; 88(8): 4229-4238.
17. Kieslich CA, Smadbeck J, Khoury GA, Floudas CA. onsSert: Consensus SVM model for accurate prediction of ordered secondary structure. J Chem Inf Model. 2016; 56(3): 455-461.
18. Obeidat M, Ding X, Fishbane N, Hollander Z, Ng RT, McManus B, et al. The effect of different case definitions of current smoking on the discovery of smoking-related blood gene expression signatures in chronic obstructive pulmonary disease. Nicotine Tob Res. 2016; 18(9): 1903-1909.
19. Beghè B, Hall IP, Parker SG, Moffatt MF, Wardlaw A, Connolly MJ, et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy. 2010; 65(4): 474-481.
20. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008; 118(11): 3546-3556.
21. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994; 150(6 Pt 1): 1646-1652.
22. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghè B, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002; 166(1): 105-110.
23. Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther. 2001; 14(3): 193-202.
24. Wuyts A, Van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben-Baruch A, et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry. 1997; 36(9): 2716-2723.
25. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656833, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011; 72(2): 282-293.
26. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep. 2004; 4(2): 123-131.
27. Durham AL, Caramori G, Chung KF, Adcock IM. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Trans Res. 2016; 167(1): 192-203.
28. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase and catabepsin-dependent emphysema. J Clin Invest. 2000; 106(9): 1081-1093.
29. van der Pouw Kraan TC, Kuijkuyckvycrak M, Bakker AM, Baggen JM, van der Zee JS, Denterman MA, et al. Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun. 2002; 3(6): 438-439.
30. Grubek-Jaworska H, Papilińska M, Hermanowicz-Salomon J, Białek-Gosk K, Dąbrowska M, Grabczak E, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration. 2012; 84(2): 101-107.
31. Turner MC, Chen Y, Krewski D, Callie EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007; 176(3): 285-290.
32. Schabath MB, Delclos GL, Martinez-Medina MM, Greisinger AJ, Lu C, Wu X, et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005; 161(5): 412-422.
33. Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK, Kim JS, et al. Chronic obstructive pulmonary disease-related non-small-cell lung cancer exhibits a low prevalence of EGFR and ALK driver mutations. PLoS One. 2015; 10(11): e0142306.
34. Coxson HO, Leipsic J, Parraga G, Sin DD. Using pulmonary imaging to move COPD beyond FEV1. Am J Respir Crit Care Med. 2014; 190(2): 135-144.
35. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1(6077): 1645-1648.
36. Tharmar M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981; 123(6): 659-664.